AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14998380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 11682440 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (16 micromol min(‐1))
Number of subjects: 32
Study 11682440 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (64 micromol min(‐1))
Number of subjects: 32
Study 11682440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined COX and NO inhibition
Number of subjects: 32
Study 9702445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (average of 15 mg daily)
Number of subjects: 26
Study 9702445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9702445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 26
Study 8081665 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone (MP) treatment
Number of subjects: 86
Study 8081665 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study 2644918 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (details on dosage and duration not specified)
Number of subjects: 50
Study 2644918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 986289 — intervention group
Group type: EXPERIMENTAL
Intervention: E.C.T. and phenothiazines
Number of subjects: 2
Study 986289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate and phenothiazines
Number of subjects: 2
Study 31778442 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal lidocaine/prilocaine gel
Number of subjects: 40
Study 31778442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine (Oraqix®)
Number of subjects: 40
Study 31778442 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 40
Study 31618241 — intervention group
Group type: EXPERIMENTAL
Intervention: HOT (34±0°C, 28.3±1.9% RH)
Number of subjects: 17
Study 31618241 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (23±0.2°C, 35.8±1.2% RH)
Number of subjects: 17
Study 28814322 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-start design
Number of subjects: 0
Study 28814322 — intervention group
Group type: COMPARATOR
Intervention: Standard parallel group RCT
Number of subjects: 0
Study 25259546 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg a.m.
Number of subjects: 1093
Study 25259546 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg p.m.
Number of subjects: 1093
Study 25259546 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 40 mg a.m.
Number of subjects: 1093
Study 23596347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl wafer
Number of subjects: 11
Study 22017889 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 277
Study 22017889 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgical repair
Number of subjects: 277
Study 18642046 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled transanal rectal resection
Number of subjects: 119
Study 18642046 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback training
Number of subjects: 119
Study 15967527 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) group
Number of subjects: 0
Study 15967527 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) group
Number of subjects: 0
Study 15967527 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 12637196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 600 IU daily
Number of subjects: 20
Study 12637196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11205095 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokEnders (SE group)
Number of subjects: 139
Study 11205095 — intervention group
Group type: COMPARATOR
Intervention: Practice as usual (GP group)
Number of subjects: 139
Study 15102393 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme
Number of subjects: 65
Study 15102393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 65
Study 8239307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training + phosphatidylserine
Number of subjects: 40
Study 8239307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training + pyritinol
Number of subjects: 40
Study 8239307 — intervention group
Group type: COMPARATOR
Intervention: Social support
Number of subjects: 40
Study 8239307 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training only
Number of subjects: 40
Study 3544640 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (4.5 mg/kg)
Number of subjects: 20
Study 3544640 — intervention group
Group type: COMPARATOR
Intervention: Enprofylline (1.5 mg/kg)
Number of subjects: 20
Study 31249185 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 100
Study 31249185 — intervention group
Group type: COMPARATOR
Intervention: Traditional dental health education (Control)
Number of subjects: 100
Study 29462733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic intervention (18% oxygen)
Number of subjects: 50
Study 29462733 — intervention group
Group type: COMPARATOR
Intervention: Control (21% oxygen)
Number of subjects: 50
Study 29462733 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HIG and CG)
Number of subjects: 50
Study 29462733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic intervention (HIG)
Number of subjects: 50
Study 26797633 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine-based nutrient drink
Number of subjects: 34
Study 26797633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23357971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (dose >17,000 mg/m)
Number of subjects: 156
Study 23357971 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (dose >15,000 mg/m)
Number of subjects: 156
Study 21782171 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured verbal information with supplementary written information
Number of subjects: 121
Study 21782171 — intervention group
Group type: COMPARATOR
Intervention: Structured verbal information
Number of subjects: 121
Study 20001434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg once daily
Number of subjects: 0
Study 17284745 — intervention group
Group type: EXPERIMENTAL
Intervention: High-folate diet with 369 mug food folate/d and a placebo capsule (Group A)
Number of subjects: 72
Study 17284745 — intervention group
Group type: COMPARATOR
Intervention: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group B, 92 microg folic acid/d)
Number of subjects: 72
Study 17284745 — intervention group
Group type: COMPARATOR
Intervention: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group C, 191 microg folic acid/d)
Number of subjects: 72
Study 17284745 — intervention group
Group type: COMPARATOR
Intervention: Low-folate diet with 73 microg food folate/d and folic acid capsules (Group D, 289 microg folic acid/d)
Number of subjects: 72
Study 14748940 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (500 mg/d)
Number of subjects: 305
Study 14748940 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin C (50 mg/d)
Number of subjects: 305
Study 14748940 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year vitamin C supplementation
Number of subjects: 305
Study 11844007 — intervention group
Group type: EXPERIMENTAL
Intervention: Living will
Number of subjects: 2853
Study 11844007 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare power of attorney
Number of subjects: 2853
Study 11844007 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for in-home death
Number of subjects: 2853
Study 11844007 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for hospice services
Number of subjects: 2853
Study 11844007 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for moral right to end life
Number of subjects: 2853
Study 11844007 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for physician-assisted dying
Number of subjects: 2853
Study 10209562 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at doses of 0.05, 0.10, or 0.20 lU/kg/day
Number of subjects: 40
Study 10209562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7933500 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthetics (sevoflurane, isoflurane, halothane) with oxygen and nitrous oxide
Number of subjects: 74
Study 7933500 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesics (diclofenac, acetaminophen suppositories, intravenous pentazocine)
Number of subjects: 74
Study 3124046 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir daily for one year
Number of subjects: 44
Study 3124046 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir during outbreaks of herpes
Number of subjects: 44
Study 30007544 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimidine plus ivermectin
Number of subjects: 144
Study 30007544 — intervention group
Group type: COMPARATOR
Intervention: Tribendimidine
Number of subjects: 144
Study 30007544 — intervention group
Group type: COMPARATOR
Intervention: Tribendimidine plus oxantel-pamoate
Number of subjects: 144
Study 30007544 — intervention group
Group type: COMPARATOR
Intervention: Albendazole plus oxantel-pamoate
Number of subjects: 144
Study 27714799 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick links home page
Number of subjects: 641
Study 27714799 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified data display
Number of subjects: 641
Study 27714799 — intervention group
Group type: COMPARATOR
Intervention: Current MPF home page
Number of subjects: 641
Study 27714799 — intervention group
Group type: COMPARATOR
Intervention: Current MPF display
Number of subjects: 641
Study 27714799 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone prescription drug plan (PDP)
Number of subjects: 641
Study 27714799 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Advantage plan with prescription drug coverage (MA-PD)
Number of subjects: 641
Study 26210808 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Access (FA)
Number of subjects: 1493
Study 26210808 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial Access (LRA)
Number of subjects: 1493
Study 26210808 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Radial Access (RRA)
Number of subjects: 1493
Study 23948440 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral multivitamin supplementation (vitamin B complex, C and E) for 24 months
Number of subjects: 2387
Study 23948440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2387
Study 21125461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 1 mg/h
Number of subjects: 413
Study 21125461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 5 mg/h
Number of subjects: 413
Study 21125461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Number of subjects: 413
Study 21125461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 18708436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 43
Study 18196636 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroliberin 500 mcg twice a day for 5 days
Number of subjects: 46
Study 18196636 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroliberin
Number of subjects: 46
Study 18196636 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 14730113 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg of Zn2+ once daily)
Number of subjects: 14
Study 14730113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 10705331 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (n = 180)
Number of subjects: 400
Study 10705331 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (n = 100)
Number of subjects: 400
Study 10705331 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (n = 100)
Number of subjects: 400
Study 9334792 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information only
Number of subjects: 248
Study 9334792 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided discussion
Number of subjects: 248
Study 9334792 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized decision exercise
Number of subjects: 248
Study 9334792 — intervention group
Group type: EXPERIMENTAL
Intervention: Carefully written information
Number of subjects: 248
Study 1438004 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen in the fed state (with water 15 min after 330 ml of apple juice)
Number of subjects: 0
Study 1438004 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen in the fasted state (with water)
Number of subjects: 0
Study 4084483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 4084483 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study 4084483 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine with prior metoclopramide treatment
Number of subjects: 0
Study 30811293 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus Rituximab (BR)
Number of subjects: 0
Study 30811293 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP/R-CVP
Number of subjects: 0
Study 29533491 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hemoporfin (5 mg/kg)
Number of subjects: 100
Study 29533491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hemoporfin (2.5 mg/kg)
Number of subjects: 100
Study 29533491 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 100
Study 26523339 — intervention group
Group type: EXPERIMENTAL
Intervention: 3R plus metacomprehension judgments
Number of subjects: 0
Study 26523339 — intervention group
Group type: EXPERIMENTAL
Intervention: JOIs with the 3R strategy
Number of subjects: 0
Study 26523339 — intervention group
Group type: COMPARATOR
Intervention: Standard 3R
Number of subjects: 0
Study 26523339 — intervention group
Group type: COMPARATOR
Intervention: Note-taking plus metacomprehension judgments
Number of subjects: 0
Study 27501207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure band applied at P6 acupuncture point for 4 days
Number of subjects: 90
Study 27501207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure applied with finger pressure at P6 acupuncture point for 4 days
Number of subjects: 90
Study 27501207 — intervention group
Group type: COMPARATOR
Intervention: Control group with routine antiemetic therapy only
Number of subjects: 90
Study 23283457 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy of dapsone and rifampicin
Number of subjects: 40
Study 23283457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone, rifampicin and clofazimine (U-MDT)
Number of subjects: 40
Study 23283457 — intervention group
Group type: EXPERIMENTAL
Intervention: U-MDT
Number of subjects: 40
Study 20594219 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation plus argon plasma coagulation
Number of subjects: 200
Study 20594219 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleroligation
Number of subjects: 200
Study 20594219 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 200
Study 20594219 — intervention group
Group type: COMPARATOR
Intervention: Variceal band ligation
Number of subjects: 200
Study 20594219 — intervention group
Group type: COMPARATOR
Intervention: Combined endoscopic sclerotherapy and band ligation
Number of subjects: 200
Study 18341562 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol lozenges (2.5 g xylitol, 3 times a day)
Number of subjects: 160
Study 18341562 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol/fluoride lozenges (1.5 mg fluoride, 3 times a day)
Number of subjects: 160
Study 18341562 — intervention group
Group type: COMPARATOR
Intervention: Reference no-tablet group (n = 70)
Number of subjects: 160
Study 16364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Low C2 (<1,000 microg/liter, n = 18)
Number of subjects: 48
Study 16364860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate C2 (1,000-1,500 microg/liter, n = 16)
Number of subjects: 48
Study 16364860 — intervention group
Group type: EXPERIMENTAL
Intervention: High C2 (>1,500 microg/liter, n = 14)
Number of subjects: 48
Study 12215081 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 120
Study 12215081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 120
Study 12215081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CM and CBT (CBT + CM)
Number of subjects: 120
Study 12215081 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (MMTP only)
Number of subjects: 120
Study 10527085 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (2mg)
Number of subjects: 3
Study 10527085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ascorbic acid, 50mg)
Number of subjects: 3
Study 7482648 — intervention group
Group type: EXPERIMENTAL
Intervention: BY963 (spherosome suspension containing a phospholipid), administered in three doses (2.5, 5, and 10 mL) at four different injection rates (0.25, 0.5, and 1 mL/s and bolus)
Number of subjects: 8
Study 7482648 — intervention group
Group type: EXPERIMENTAL
Intervention: BY963 (spherosome suspension containing a phospholipid)
Number of subjects: 8
Study 1932407 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 40
Study 1932407 — intervention group
Group type: EXPERIMENTAL
Intervention: fluoxetine
Number of subjects: 40
Study 1932407 — intervention group
Group type: COMPARATOR
Intervention: control (normal healthy volunteers)
Number of subjects: 40
Study 6319244 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse wheat bran
Number of subjects: 0
Study 6319244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30276532 — intervention group
Group type: COMPARATOR
Intervention: PH1-T (after combined kidney liver transplantation)
Number of subjects: 115
Study 30276532 — intervention group
Group type: COMPARATOR
Intervention: PH1-Cons (under conservative treatment)
Number of subjects: 115
Study 30276532 — intervention group
Group type: COMPARATOR
Intervention: Cont-T (patients with a past of renal transplantation)
Number of subjects: 115
Study 30276532 — intervention group
Group type: COMPARATOR
Intervention: Cont-H (healthy controls)
Number of subjects: 115
Study 28661195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (standard course)
Number of subjects: 50
Study 28661195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (optimised course)
Number of subjects: 50
Study 27084025 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐week behavioral, positive parenting, and peer monitoring skills intervention
Number of subjects: 89
Study 27084025 — intervention group
Group type: COMPARATOR
Intervention: General health education comparison condition
Number of subjects: 89
Study 24976429 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged black garlic (ABG), 6 g/d, twice daily for 12 weeks
Number of subjects: 60
Study 24976429 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 12 weeks
Number of subjects: 60
Study 23084274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulip fibre
Number of subjects: 174
Study 23084274 — intervention group
Group type: COMPARATOR
Intervention: Bare fibre
Number of subjects: 174
Study 23084274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulip fibre and Bare fibre
Number of subjects: 174
Study 20671623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger neo-minophagen C (SNMC)
Number of subjects: 36
Study 20671623 — intervention group
Group type: COMPARATOR
Intervention: S-adenosyl-L-methionine (SAM)
Number of subjects: 36
Study 17950791 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus planned glycoprotein IIb/IIIa inhibitor (GPI)
Number of subjects: 6001
Study 17950791 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin plus provisional GPIs
Number of subjects: 6001
Study 17950791 — intervention group
Group type: EXPERIMENTAL
Intervention: Major hemorrhage
Number of subjects: 6001
Study 16343666 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (Aspirin)
Number of subjects: 0
Study 16343666 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (Warfarin)
Number of subjects: 0
Study 16343666 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 14769724 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing method
Number of subjects: 12
Study 14769724 — intervention group
Group type: COMPARATOR
Intervention: Dosimeter method
Number of subjects: 12
Study 10714084 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthmatics
Number of subjects: 35
Study 10714084 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe asthmatics
Number of subjects: 35
Study 8960591 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium score of 5 using fast computed tomography
Number of subjects: 100
Study 8960591 — intervention group
Group type: COMPARATOR
Intervention: Smooth, luminally normal coronary arteries
Number of subjects: 100
Study 1389192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation 40 mg
Number of subjects: 80
Study 1389192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine inhalation 120 mg
Number of subjects: 80
Study 1389192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) lidocaine 1 mg/kg
Number of subjects: 80
Study 1389192 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation (placebo)
Number of subjects: 80
Study 3158325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 10
Study 3158325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 10
Study 3158325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg
Number of subjects: 10
Study 3158325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg
Number of subjects: 10